| Molecule | Cat. No. | Product Name | Species | Host | Structure | Purity | Activity | Size&Price |
|---|---|---|---|---|---|---|---|---|
| TDP-43 | Human TDP-43 Protein, His Tag | Human | E. coli | ![]() | SDS-PAGE | $145.00 25ug |
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Monepantel | PPL-1; NUZ-001 | Phase 3 Clinical | Pitney Pharmaceuticals Pty Ltd | Amyotrophic Lateral Sclerosis; Motor Neuron Disease; Neoplasms | Details |
| nL-TARD-001 | nL-TARD-001 | Phase 2 Clinical | N-Lorem Foundation | Amyotrophic Lateral Sclerosis | Details |
| AMDX-2011P | AMDX2011P; AMDX-2011P | Phase 2 Clinical | Amydis Inc | Alzheimer Disease; Amyotrophic Lateral Sclerosis; Cerebral Amyloid Angiopathy; Glaucoma, Open-Angle; Parkinson Disease | Details |
| VTx-002 (VectorY) | VTx-002 | Phase 2 Clinical | VectorY BV | Amyotrophic Lateral Sclerosis | Details |
| CTx-1000 | CTx1000; CTx-1000 | Phase 1 Clinical | Celosia Therapeutics Pty Ltd | Amyotrophic Lateral Sclerosis | Details |
| AB-14 | AB-14 | Phase 1 Clinical | Autotac Bio Inc | Amyotrophic Lateral Sclerosis | Details |
